Transversus Abdominis Plane Catheter Following Kidney Transplantation
Continuous Infusion of Local Anesthetic After Kidney Transplantation
This is a phase III, randomized, double-blinded, sham-controlled trial comparing the use of a continuous infusion of local anesthetic via transversus abdominis plane (TAP) catheter to a saline infusion (sham) via TAP catheter along with standard postoperative analgesia in patients undergoing kidney transplantation. Patients will have a TAP catheter placed at the time of kidney transplantation by the surgical team under direct vision. They are then randomized to a continuous infusion of local anesthetic or saline for 48 hours postoperatively. Both groups will receive a standard postoperative analgesic regimen including a Patient Controlled Analgesic (PCA) pump and multimodal analgesics including acetaminophen and gabapentin.
調査の概要
研究の種類
入学 (予想される)
段階
- フェーズ 3
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male, female, non-binary gender, aged >18 years.
- Undergoing a kidney transplant (deceased or living donor) as treatment for stage 5 chronic kidney disease (Glomerular filtration rate < 15ml/min) either on dialysis, or approaching dialysis
- No history of allergy to any local anesthetic.
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
Exclusion Criteria:
- Current use of opioid pain medications prior to kidney transplantation.
- Known allergic reactions to components of any local anesthetic medication.
- Prior local anesthetic systemic toxicity.
- History of chronic pain undergoing current active treatment for the same.
- Age <18 years (this analgesic approach has not been established in this population).
- Unable or unwilling to use IV PCA pump for any reason (manual dexterity, cognitive impairment, patient choice etc.).
- Multi-visceral transplantation.
- Incision other than standard Gibson incision.
- Unilateral or bilateral nephrectomy at time of kidney transplant.
- Advanced liver disease.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ：Local Anaesthetic Infusion
|
Ropivacaine infusion via transversus abdominis plane catheter.
|
|
偽コンパレータ：Saline Infusion
|
Saline infusion via transversus abdominis plane catheter.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Oral morphine equivalent (OME)
時間枠：48 hours post kidney transplantation
|
OME in mg
|
48 hours post kidney transplantation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Visual Analog Scale pain rating
時間枠：12, 24, and 48 hours post kidney transplantation
|
Series of 5 faces that depict discomfort levels ranging from severe pain (score 5) to no pain at all (score 1).
The higher the score, the more pain a patient has.
|
12, 24, and 48 hours post kidney transplantation
|
|
Patient quality of life score
時間枠：48 hours post kidney transplantation
|
48 hours post kidney transplantation
|
|
|
Time to return of bowel function postoperatively
時間枠：Duration of admission
|
Duration of admission
|
|
|
Incidence of local anesthetic systemic toxicity
時間枠：Duration of admission
|
Duration of admission
|
|
|
Postoperative adverse events (surgical)
時間枠：Duration of admission
|
Duration of admission
|
|
|
Delayed graft function
時間枠：Duration of admission
|
Defined as the requirement for hemodialysis/peritoneal dialysis within the first 7 days after kidney transplantation for any reason.
|
Duration of admission
|
|
Creatinine (mmol/L) at time of discharge
時間枠：Duration of admission
|
Duration of admission
|
|
|
Length of stay
時間枠：Duration of admission
|
Duration of admission
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。